It’s always fun to see startups with cool ideas in the regenerative medicine space and a new one called GC Therapeutics got some nice coverage this week. What do you think the name of this firm stands for? I have one main idea I mention below. Before we jump into it, I want to introduce […]
I’ve met people who are excited about using stem cells for Parkinson’s Disease. Some of these folks have Parkinson’s or are loved ones. Talking to them makes things real. It feel personal and not just scientific. The current treatment options are far away from what is needed for many people. I am optimistic that a
Weekly reads: Parkinson’s & the gut, sports, cat stem cells Read More »
How is research looking on stem cells for diabetes? I’m feeling more encouraged about the clinical research in that area. Before we jump into that let’s talk about two other things. The big news of the week was the felony plea deal by Liveyon’s John Kosolcharoen to charges related to marketing an unapproved cell therapy
How are things going with regenerative medicine and stem cells in Japan? It’s still an exciting time there, but I’ve noted a sense that it is a time of transition too in some ways. For example, government funding is perhaps less certain than in the past. Let’s start with a few articles on how the
Recommended reads: Stem cells in Japan, iPS cells for COVID & hearts, He Jiankui Read More »
Stem cell hype is a big problem these days. It’s been going on for decades. Even some generally good citizens of the stem cell and regenerative medicine arena engage in it at times. Maybe a few of them don’t even realize what they are doing. I think a few journalists occasionally fall into the hype
Recommended reads: 3 infected in Mexico, stem cell hype, hearing restoration Read More »
If you remember Monty Python, then you probably recall John Cleese. We’ll start with Cleese’s stem cell baloney. Not spam. Secret to eternal youth? John Cleese extols virtues of stem cell treatment, The Guardian. I’ve written before about John Cleese’s stem cell anti-aging efforts. As I told the author of The Guardian piece, I love
Utah appears ready to pass a new stem cell law that would explicitly allow clinical use of non-FDA-approved placental cell drug therapies in the state. Bill 199 seems likely to set up a conflict with the FDA that may land in court. The key part of the bill says: “A health care provider whose scope
Vertex Pharmaceuticals has a lot going for it right now on the cell therapy front. For instance, they have the strongest type 1 diabetes cell therapy pipeline after some recent acquisitions. Still it’s not a simple matter to succeed in the cell therapy space even with one therapy for one targeted disease. Trials are tough
Weekly reads: Vertex, stem cells for MS, Athersys, 900-day paper review at Nature Read More »
A reader of The Niche recently asked me, “What about stem cells for deafness?” It’s a great question and, as they pointed out, stem cells for vision loss gets much more attention. I’ve covered the translational progress of stem cells to treat many diseases but there has been less progress for deafness in the regenerative
Long-term hope on stem cells for deafness Read More »
Each year I make predictions for the stem cell and regenerative medicine field for the following year. Today’s prediction post is focused on what to expect in 2024. You can also see my stem cell predictions for 2023 and my grades on how I did. I also have made a video version of these predictions so please
20 stem cell & regenerative medicine predictions for 2024 Read More »